NCT03988530View on ClinicalTrials.gov

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 7, 2019

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions
Motion Sickness
Interventions
DRUG

Scopolamine

Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).

OTHER

Placebo Nasal Gel

Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.

Trial Locations (1)

90806

Collaborative Neuroscience Network, LLC, Long Beach

All Listed Sponsors
lead

Repurposed Therapeutics, Inc.

INDUSTRY

NCT03988530 - Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects | Biotech Hunter | Biotech Hunter